Display options
Share it on

Basic Clin Pharmacol Toxicol. 2019 Oct 09; doi: 10.1111/bcpt.13335. Epub 2019 Oct 09.

Obviously nine believers: Actionable germline genetic variants for pre-emptive pharmacogenetic testing.

Basic & clinical pharmacology & toxicology

Per Damkier

Affiliations

  1. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
  2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

PMID: 31597220 DOI: 10.1111/bcpt.13335

[No abstract available.]

Keywords: clinical pharmacogenomics; dissemination of research; pharmacogenetics/pharmacogenomics; precision medicine; rational pharmacotherapy

References

  1. van der Wouden CH, van Rhenen MH, Jama W, et al. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. Clin Pharmacol Ther. 106(4):866-873. - PubMed
  2. Collins F.The future of genomics. NHGRI; 2003. https://www.genome.gov/11007447/2003-francis-collins-testimony-the-future-of-genomics. Accessed August 13, 2019. - PubMed
  3. Joyner MJ, Paneth N. Promises, promises, and precision medicine. J Clin Invest 2019;129:946-948. - PubMed
  4. Pharmacogenetics GA. Chasing perfection. Clin Pharmacol Ther 2019;106:265-270. - PubMed
  5. Peterson JF, Roden DM, Orlando LA, Ramirez AH, Mensah GA, Williams MS. Building evidence and measuring clinical outcomes for genomic medicine. Lancet. 394(10198):604-610. - PubMed

Publication Types